On April 1, 2026, the U.S. Food and Drug Administration (FDA) approved another treatment option for chronic weight management with Eli Lilly and Company’s Foundayo™ (orforglipron – Lilly). The once-daily, oral medication is available for adults with obesity or adults who are overweight with at least one weight‑related medical condition.
About Foundayo
Launching on April 6, 2026, Foundayo is a small‑molecule glucagon‑like peptide‑1 (GLP‑1) receptor agonist that helps reduce excess body weight when used in combination with a reduced‑calorie diet and increased physical activity. Unlike oral peptide GLP‑1 therapies, Foundayo is available in 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, 17.2mg tablets and, unlike other oral peptide GLP‑1 therapies, it can be taken at any time of day without food or water restrictions.
Leading to the approval was a global phase III ATTAIN clinical development program with more than 4,500 obese or overweight adults. Patients who received the highest dose of Foundayo achieved an average weight loss of approximately 27 pounds (12.4%) at 72 weeks compared to 2.2 pounds (0.9%) with placebo. Treatment was also associated with improvements in cardiometabolic risk markers, including reductions in waist circumference, lipid parameters, and blood pressure.
Obesity in workers’ compensation claims
According to the Centers for Disease Control and Prevention (CDC), over 40% of adults aged 20 years and older are considered obese. This chronic disease requires long-term management and is associated with serious health consequences and decreased life expectancy. In workers’ compensation claims, obesity can hinder recovery from injuries and increase the time to return to work or maximum medical improvement (MMI). It can also hinder the ability of a patient to participate in various treatment modalities and diminishes the ability to have surgery.
MyMatrixx by Evernorth Actions
MyMatrixx by Evernorth is dedicated to helping our clients monitor and manage the cost and utilization of injury-related medications and the medications that may aid in an injured worker’s overall recovery. We will continue to evaluate workers' compensation claim-related uses for all GLP-1 agonists/GIP dual agonists to determine if they are an appropriate addition to our formularies. If you have any questions, please reach out to your MyMatrixx account team.